Literature DB >> 7108670

Anticoagulant therapy by continuous heparinization in newborn and older infants.

M M McDonald, W E Hathaway.   

Abstract

In order to evaluate the metabolism and anticoagulant effect of heparin in the newborn infant and young child, 15 babies were monitored during continuous intravenous heparinization for documented large vessel thromboses. Infants with the most significant thromboses had the highest clearance rates for heparin. Plasma heparin levels in the therapeutic range (0.3 to 0.5 U/ml) and clinical resolution of the thrombi were associated with heparin doses of 16 to 35 U/kg/hour (mean = 27 U/kg/hour). A micro whole blood clotting time was evaluated and shown to be a useful guide to heparin effect in these infants. With the exception of excessive oozing from puncture sites in one infant, no complications of heparin therapy were noted. The newborn infant appears to require a larger amount of heparin than adults in order to achieve adequate heparinization.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108670     DOI: 10.1016/s0022-3476(82)80086-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Vascular compromise in newborn infants.

Authors:  D T Gault
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

Review 2.  How I treat venous thrombosis in children.

Authors:  Marilyn J Manco-Johnson
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

3.  Neonatal portal vein thrombosis successfully treated by regional streptokinase infusion.

Authors:  V K Rehan; C M Cronin; J M Bowman
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 5.  Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.

Authors:  P C Rimensberger; J R Humbert; M Beghetti
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Authors:  M T Nurmohamed; H ten Cate; J W ten Cate
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

7.  Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.

Authors:  R von Kries; H Stannigel; U Göbel
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

8.  Pharmacokinetics of protein C and antithrombin in the fetal lamb: a model to predict human neonatal replacement dosing.

Authors:  Marilyn J Manco-Johnson; Michele R Hacker; Linda J Jacobson; William W Hay
Journal:  Neonatology       Date:  2008-11-27       Impact factor: 4.035

Review 9.  Hematologic and oncologic complications in the critically ill child.

Authors:  S McIntosh
Journal:  Yale J Biol Med       Date:  1984 Mar-Apr
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.